Xiaoxi Yao

Xiaoxi Yao

Auto-generated profile, based on publicly available information

Xiaoxi Yao

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in JACC
Verified
Journal Article
Closed access
XYXiaoxi Yao
Xiaoxi Yao
NSNilay D. Shah
Nilay D. Shah
LSLindsey R. Sangaralingham
Lindsey R. Sangaralingham
BGBernard J. Gersh
Bernard J. Gersh
PNPeter A. Noseworthy
Peter A. Noseworthy

6 May 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
XYXiaoxi Yao
Xiaoxi Yao
DRDavid R. Rushlow
David R. Rushlow
JIJonathan W. Inselman
Jonathan W. Inselman
RMRozalina G. McCoy
Rozalina G. McCoy
TTTom Thacher
Tom Thacher
PNPeter A. Noseworthy
Peter A. Noseworthy

23 February 2016 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
XYXiaoxi Yao
Xiaoxi Yao
NANeena S. Abraham
Neena S. Abraham
GAG. Caleb Alexander
G. Caleb Alexander
WCWilliam Crown
William Crown
VMVictor M. Montori
Victor M. Montori
PNPeter A. Noseworthy
Peter A. Noseworthy
Background: In comparison to warfarin, non–vitamin K antagonist oral anticoagulants ( NOAC s) have the advantages of ease of dosing, fewer drug interactions, and lack of need for ongoing monitoring. We sought to evaluate whether these advantages translate to improved adherence and whether adherence is associated with improved outcomes in patients with atrial fibrillation. Methods and Results: We performed a retrospective cohort analysis by using a large US commercial insurance database to identify 64 661 patients with atrial fibrillation who initiated warfarin, dabigatran, rivaroxaban, or apixaban treatment between November 1, 2010, and December 31, 2014. During a median of 1.1 y of follow‐up, 47.5% of NOAC patients had a proportion of days covered of ≥80%, compared with 40.2% in warfarin patients ( P <0.001). Patients with CHA 2 DS 2 ‐ VAS c (risk based on the presence of congestive heart failure, hypertension age 65–74 y, age ≥75 y, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, sex category) score ≥4 were at increased risk of stroke when they were not taking anticoagulation ≥1 month versus <1 week (1–3 months: hazard ratio [ HR ] 1.96, 3–6 months: HR 2.64, ≥6 months: HR 3.66; all P <0.001). Patients with CHA 2 DS 2 ‐ VAS c score 2 or 3 were at increased risk of stroke when they were not taking anticoagulation ≥6 months ( HR 2.73, P <0.001). In these patients with CHA 2 DS 2 ‐ VAS c score ≥2, nonadherence was not associated with intracranial hemorrhage. Among patients with CHA 2 DS 2 ‐ VAS c score 0 or 1, time not taking anticoagulation was not associated with stroke, but not taking anticoagulation ≥3 months was associated with a significant reduction of bleeding. Conclusions: Adherence to anticoagulation is poor in practice and may be modestly improved with NOAC s. Adherence to therapy appears to be most important in patients with CHA 2 DS 2 ‐ VAS c score ≥2, whereas the benefits of anticoagulation may not outweigh the harms in patients with CHA 2 DS 2 ‐ VAS c score 0 or 1.

13 June 2016 in Journal of the American Heart Association
Verified
Journal Article
Open access
XYXiaoxi Yao
Xiaoxi Yao
NANeena S. Abraham
Neena S. Abraham
LSLindsey R. Sangaralingham
Lindsey R. Sangaralingham
MBM. Fernanda Bellolio
M. Fernanda Bellolio
RMRobert D. McBane
Robert D. McBane
PNPeter A. Noseworthy
Peter A. Noseworthy
Background: The introduction of non–vitamin K antagonist oral anticoagulants has been a major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in clinical trials may not translate to routine practice. We aimed to evaluate the effectiveness and safety of dabigatran, rivaroxaban, and apixaban by comparing each agent with warfarin. Methods and Results: Using a large US insurance database, we identified privately insured and Medicare Advantage patients with nonvalvular atrial fibrillation who were users of apixaban, dabigatran, rivaroxaban, or warfarin between October 1, 2010, and June 30, 2015. We created 3 matched cohorts using 1:1 propensity score matching: apixaban versus warfarin (n=15 390), dabigatran versus warfarin (n=28 614), and rivaroxaban versus warfarin (n=32 350). Using Cox proportional hazards regression, we found that for stroke or systemic embolism, apixaban was associated with lower risk (hazard ratio [ HR ] 0.67, 95% CI 0.46–0.98, P =0.04), but dabigatran and rivaroxaban were associated with a similar risk (dabigatran: HR 0.98, 95% CI 0.76–1.26, P =0.98; rivaroxaban: HR 0.93, 95% CI 0.72–1.19, P =0.56). For major bleeding, apixaban and dabigatran were associated with lower risk (apixaban: HR 0.45, 95% CI 0.34–0.59, P <0.001; dabigatran: HR 0.79, 95% CI 0.67–0.94, P <0.01), and rivaroxaban was associated with a similar risk ( HR 1.04, 95% CI 0.90–1.20], P =0.60). All non–vitamin K antagonist oral anticoagulants were associated with a lower risk of intracranial bleeding. Conclusions: In patients with nonvalvular atrial fibrillation, apixaban was associated with lower risks of both stroke and major bleeding, dabigatran was associated with similar risk of stroke but lower risk of major bleeding, and rivaroxaban was associated with similar risks of both stroke and major bleeding in comparison to warfarin.

1 November 2017 in JACC
Verified
Journal Article
Closed access
XYXiaoxi Yao
Xiaoxi Yao
NTNavdeep Tangri
Navdeep Tangri
BGBernard J. Gersh
Bernard J. Gersh
LSLindsey R. Sangaralingham
Lindsey R. Sangaralingham
NSNilay D. Shah
Nilay D. Shah
PNPeter A. Noseworthy
Peter A. Noseworthy

1 December 2016 in Chest
Verified
Journal Article
Closed access
PNPeter A. Noseworthy
Peter A. Noseworthy
XYXiaoxi Yao
Xiaoxi Yao
NANeena S. Abraham
Neena S. Abraham
LSLindsey R. Sangaralingham
Lindsey R. Sangaralingham
RMRobert D. McBane
Robert D. McBane
NSNilay D. Shah
Nilay D. Shah